October 30th 2024
The FDA is currently evaluating the application of intravesical mitomycin for low-grade intermediate-risk non–muscle-invasive bladder cancer.
October 21st 2024
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Analyzing Frontline Options for Patients With Bladder Cancer
October 29th 2018Thomas Powles, MD, shares his advice for community oncologists treating patients with bladder cancer in the frontline setting. According to Powles, this is a setting where there is a lot of uncertainty that can make decision making difficult.
Watch
Exploring Response and Resistance to Checkpoint Inhibitor Therapy in Bladder, Other GU Cancers
October 29th 2018Padmanee Sharma, MD, PhD, discusses the development of checkpoint inhibitors in several cancers, including urothelial carcinoma, RCC, and prostate cancer. She also addresses the challenges in resistance to these agents and where some clinical trials are moving forward in the field.
Read More
Promising Antitumor Activity Seen With Pembrolizumab in NMIBC
October 29th 2018According to results from an interim analysis of an ongoing single-arm open-label phase II study, pembrolizumab demonstrated promising antitumor activity in patients with high-risk nonmuscle invasive bladder cancer that are unresponsive to Bacillus Calmette-Guérin and refused or were ineligible for cystectomy.
Read More
Despite Advances, Interpreting Data From Genomics and Precision Medicine Lags
October 25th 2018I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.
Read More
Higher Dose of Ipilimumab Plus Nivolumab Demonstrates Benefit in Bladder Cancer
October 25th 2018The treatment regimen of nivolumab (Opdivo) at 1 mg/kg plus ipilimumab at (Yervoy) 3 mg/kg induced higher overall response rates and longer progression-free survival in patients with platinum-pretreated metastatic urothelial carcinoma, according to extended follow-up data reported at the 2018 ESMO Annual Congress.<br />
Read More
Financial Advocacy Grows Under the Value-Based System
October 24th 2018Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.
Read More
ACCC President Reignites Resilience in Oncology Caregivers
October 23rd 2018Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Watch
Larotrectinib Induces 80% ORR in Advanced NTRK+ Solid Tumors
October 22nd 2018Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored <em>NTRK </em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.
Read More
CMS Tackles Drug Prices, But What Does This Mean for Patient Care Access?
October 19th 2018Rising prescription drug prices continue to add to the burden of paying for quality healthcare. In an effort to confront such costs, the Centers for Medicare & Medicaid Services has rescinded a prohibition on step therapy for Medicare Advantage plans. But some contend such a policy will reduce patient access to optimal medication.
Read More
Erdafitinib Submitted to FDA for Approval in Urothelial Carcinoma
September 19th 2018The FDA has received a new drug application for erdafitinib as a treatment for patients with locally advanced or metastatic urothelial carcinoma and <em>FGFR</em> genetic alterations whose tumors progressed following chemotherapy, Janssen, the manufacturer of the oral pan-FGFR tyrosine kinase inhibitor, has announced.
Read More
Current and Emerging Immunotherapy Strategies in Advanced Urothelial Cancers
August 20th 2018Until recently, therapeutic options for the management of advanced urothelial cancers have been limited to traditional cytotoxic agents with modest efficacy. However, the brisk pace of recent discovery in the field of immunotherapy and molecular therapeutics has ushered in a new era for management of patients with urothelial carcinoma.
Read More